Clinical Trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Protocol Amendment History 8 changes
notable Trial sites expanded: 154 -> 158 locations 2026-07-28
notable Trial sites expanded: 149 -> 154 locations 2026-07-11
notable Trial sites expanded: 145 -> 149 locations 2026-06-24
notable Trial sites expanded: 136 -> 145 locations 2026-06-09
notable Trial sites expanded: 126 -> 136 locations 2026-05-23
notable Trial sites expanded: 120 -> 126 locations 2026-05-09
notable Trial sites expanded: 116 -> 120 locations 2026-04-23
notable Trial sites expanded: 112 -> 116 locations 2026-04-10
Trial Details
NCT Number NCT07018323
Lead Sponsor Immunovant Sciences GmbH
Conditions Graves' Disease
Enrollment 210 participants
Start Date 2025-06-19
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12